Trulicity Half-Life and Pharmacokinetics, Straight From the FDA Label

This is a reference page. Its job is to reproduce, accurately and with attribution, the pharmacokinetic statements in the FDA-approved United States prescribing information for Trulicity, so somebody keeping a personal medication record can see where the numbers come from.

It is not medical advice. It has not been written or reviewed by a clinician, and it makes no recommendation about whether any medication is appropriate for anybody. It does not tell you how much to take, when to take it, or when to change anything.

If you want guidance rather than reference material, the right next step is your prescriber or pharmacist.

All figures on this page come from one document: TRULICITY (dulaglutide) injection, for subcutaneous use — the United States Prescribing Information approved by the FDA, read on DailyMed accessed 1 September 2026. The pharmacokinetic statements sit in Section 12.3, Pharmacokinetics. The label records an Initial U.S. Approval of 2014.

Dulaglutide is a longer-established agent than most of the others covered in this pillar, and it is worth noting that a longer time on the market means more secondary sources repeating figures about it — which in turn means more opportunities for a number to drift from what the label says. The bioavailability section below is a case in point.

Labels are revised, which is why the access date is printed beside each figure. If a number here ever conflicts with the current label, the current label wins.

This is the most important thing on the page.

Section 12.3 states that the mean absolute bioavailability of dulaglutide following subcutaneous administration of single 0.75 mg and 1.5 mg doses was 65% and 47% respectively. It then adds that absolute subcutaneous bioavailability for the 3 mg and 4.5 mg doses was estimated to be similar to 1.5 mg, although this has not been specifically studied.

There is no single labeled bioavailability figure for dulaglutide. The label reports two measured values at two doses, and an explicit estimate — flagged as unstudied — for the higher doses.

This matters because reference tables and tracking software almost always carry one number per medication, and dulaglutide does not fit that shape: a single figure such as 50% matches neither labeled value. What is published here is what the label states: 65% at 0.75 mg, 47% at 1.5 mg, and an unstudied estimate above that.

A reader meeting two bioavailability numbers for one medication may reasonably wonder which is correct. Both are. They describe different doses.

Absolute bioavailability is the fraction of an administered dose reaching systemic circulation, and there is no rule requiring that fraction to stay constant as dose size changes. Absorption from a subcutaneous depot depends on processes that need not scale linearly with the amount deposited, and the label reports what was measured rather than what would be tidier.

The honest presentation is the label's own: state both values, attach each to its dose, and carry the label's caveat about the higher doses rather than quietly dropping it. A page that picks one figure and presents it as "dulaglutide bioavailability" has made a decision the label declined to make.

Section 12.3 gives an elimination half-life of approximately 5 days, and states that maximum plasma concentration was observed between 24 and 72 hours following subcutaneous administration.

With a once-weekly interval and a five-day half-life, each dose arrives while a substantial proportion of the previous one remains, so levels build across the first several doses before flattening — the same accumulation pattern the other weekly agents in this class show.

On timing, the label again gives a window rather than a point. Twenty-four to seventy-two hours is a three-fold range, and a reference table showing a single figure has selected a value from inside it. That selection is a modelling convenience and should be described as one.

Trulicity is escalated rather than started at a maintenance level, and the prescribing information describes that escalation in its dosage and administration section.

This page does not reproduce it — not the steps, not the intervals, not the conditions for moving between them. The information is public, but a titration schedule is only meaningful attached to a specific person, and a page that publishes one hands readers a plan nobody qualified has given them.

A stepwise schedule exists, it is defined in the label, and it is applied to you by your prescriber. A record's job begins afterwards.

GLP-1 Tracker records what you enter: the date of each dose you log, the injection site you noted, weight and BMI entries added over time, meals captured through the photo scan with calories, protein and fiber estimated, and notes about how a week went.

It holds those together in one timeline rather than scattered across a notes app, a paper diary and memory. For a medication somebody may have been taking for years, that continuity is the whole value — a long record answers questions a recent one cannot.

What the app does not do is decide anything. It does not evaluate whether your routine is working, it does not flag anything as clinically significant, and it does not generate schedules.

GLP-1 Tracker includes an educational medication-level view that draws a curve from logged doses and a published half-life figure of the kind quoted on this page.

Dulaglutide is a good illustration of the limits of that approach. Because the labeled bioavailability differs by dose, any curve that applies one absorption assumption across a person's whole history is making a simplification the label does not support. The curve is still useful for seeing why a weekly medication accumulates over the first month; it is not a description of anybody's actual exposure.

It is built from population-level label figures, not from you. It cannot account for your body weight, your kidney function, injection-site variation or ordinary biological variability. It is not a measurement, not a blood level, and not a clinical reading, and it should never influence a dose.